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Abstract
Background: Acinetobacter baumannii is an emerging nosocomial pathogen worldwide with increasing prevalence of 
multi-drug and pan-drug resistance. A. baumannii exists widely in natural environment, especially in health care 
settings, and has been shown difficult to be eradicated. Bacteriophages are often considered alternative agent for 
controlling bacterial infection and contamination. In this study, we described the isolation and characterization of one 
virulent bacteriophage AB1 capable of specifically infecting A. baumannii.
Results: A virulent bacteriophage AB1, specific for infecting a clinical strain A. baumannii KD311, was first isolated from 
marine sediment sample. Restriction analysis indicated that phage AB1 was a dsDNA virus with an approximate 
genome size of 45.2 kb to 46.9 kb. Transmission electron microscopy showed that phage AB1 had an icosahedral head 
with a non-contractile tail and collar or whisker structures, and might be tentatively classified as a member of the 
Siphoviridae family. Proteomic pattern of phage AB1, generated by SDS-PAGE using purified phage particles, revealed 
five major bands and six minor bands with molecular weight ranging from 14 to 80 kilo-dalton. Also determined was 
the adsorption rate of phage AB1 to the host bacterium, which was significantly enhanced by addition of 10 mM CaCl2. 
In a single step growth test, phage AB1 was shown having a latent period of 18 minutes and a burst size of 409. 
Moreover, pH and thermal stability of phage AB1 were also investigated. At the optimal pH 6.0, 73.2% of phages 
survived after 60 min incubation at 50°C. When phage AB1 was used to infect four additional clinical isolates of A. 
baumannii, one clinical isolate of Stenotrophomonas maltophilia, and Pseudomonas aeruginosa lab strains PAK and 
PAO1, none of the tested strains was found susceptible, indicating a relatively narrow host range for phage AB1.
Conclusion: Phage AB1 was capable of eliciting efficient lysis of A. baumannii, revealing its potential as a non-toxic 
sanitizer for controlling A. baumannii infection and contamination in both hospital and other public environments.
Background
Acinetobacter baumannii is a nonfermentative, nonmo-
tile, catalase-positive, gram-negative bacterium found in
soil, water, sewage, and many health care environments.
A. baumannii is also a commensal microbe existing on
human skin and mucous membrane, capable of opportu-
nistic infections, especially in immunocompromised
individuals, including pneumonia, meningitis, septicae-
mia, and urinary tract infection [1,2]. Since its first dis-
covery,  A. baumannii has become resistant to many
common antibiotics due to both intrinsic mechanisms
and its capability to acquire drug resistance determi-
nants. The increasing prevalence of multi-drug and pan-
drug resistant A. baumannii strains found in clinics has
rendered it one of the few important nosocomial patho-
gens, only next to Pseudomonas aeruginosa among non-
fermentative gram-negative bacteria [3,4]. A. baumannii
is resistant to dehydration, UV radiation, common chem-
ical sanitizers, and detergents, making it extremely diffi-
cult to eradicate A. baumannii contaminations from
hospital settings, especially catheter-related devices used
in intensive care units (ICU). In fact, regular antimicro-
bial agents only inhibit its growth. Currently, there are no
procedures available for removing A. baumannii in hos-
pital environments, greatly increasing the risk of hospital-
ized patients, especially patients in ICU, to the infection
by antibiotic-resistant A. baumannii [5,6].
Recently, there have been renewed interests in the
researches and applications of bacteriophages as antibac-
terial agent, partly due to their specificity in targeting and
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lysing host bacteria [7-9]. Discovered over one hundred
years ago, bacteriophages have been successfully used in
the treatments of various infectious diseases. As an alter-
native to antibiotic therapy, bacteriophage therapy is
potentially a powerful approach for the treatment of bac-
t e r i a l  i n f e c t i o n ,  e s pe c i a l l y  w h e n  a n t i b i o t i c  r e s i s t a n c e  i s
increasingly becoming a serious challenge facing the
medical community [10,11]. Recently, bacteriophage
preparations have been approved by the Food and Drug
Administration of USA as a food additive in ready-to-eat
products to prevent foodborne bacterial diseases [12].
Animal tests of phage therapy are being conducted for
treatments of various bacteria infections, and many lytic
phages have been isolated and tested for such applica-
tions [13].
Phages specific to Acinetobacter  genus were isolated
and subsequently used in phage-typing of Acinetobacter
spp.  isolates [14,15]. Using an animal model, Soothill
examined phage efficacy against infections caused by A.
baumannii. Specifically, tested mice survived the other-
wise lethal challenge of 5 LD50 (1 × 108) cells of a virulent
A. baumannii strain, when protected by as few as 102 PFU
of one lytic Acinetobacter phage [16,17]. However, to our
best knowledge, no detailed characterizations on any lytic
A. baumannii phages have been reported [18,19]. In this
paper, clinical isolates of A. baumannii were collected
and used as indicator hosts for screening phages in
marine sediment sample. Virulent phage AB1 was iso-
lated and characterized. The results showed phage AB1
as a double-stranded DNA bacterial virus capable of effi-
ciently lysing A. baumannii KD311.
Results
Identification of A. baumannii clinical strains
Before starting phage screening, clinically isolated Acine-
tobacter spp. strains were first confirmed the identity of
the A. baumannii by using sequence information derived
from their 16S rRNA gene. As described in Material and
Methods, DNA fragment containing 16S rRNA gene
from each clinical isolate was PCR-amplified and
sequenced. The resulted sequences were deposited to
GenBank and aligned to search for the most similar
sequences. Five collected clinical strains (KD311, KD312,
KD331, KD332, and KD334) were validated to be A. bau-
mannii and KD335 was Stenotrophomonas maltophilia,
one pathogen often isolated accompanying with A. bau-
mannii infections.
Bacteriophage isolation
Five A. baumannii clinical isolates were used as indicator
strains for virulent bacteriophages screening from marine
sediment samples. After enrichment, phage-containing
samples were plated onto semi-solid agar plates with the
indicator strain forming a bacterial lawn, and plaques
were allowed to form by incubating at 35°C for 4 hours.
Clear plaques were obtained from these samples only
when strain KD311 served as the indicator, with plaques
forming at size of about 1-2 mm in diameter. The phage
isolate (named AB1) was selected for further study.
Restriction fragment analysis of genomic DNA
Phage AB1 was amplified and its genomic DNA extracted
as described. Purified genomic DNA was digested with
several restriction endonucleases or their combiantions,
including  ApaI,  BamHI,  BglII,  EcoRI,  EcoRV,  HindIII,
KpnI,  NcoI,  PstI,  PvuII,  SalI,  SphI,  XbaI,  BglII/XbaI,
EcoRI/BglII, and EcoRI/XbaI, and subsequently subjected
to electrophoretic analyses. As shown in Fig. 1, out of the
tested enzymes, the enzyme combinations generated
clear DNA patterns. Based on the digestion profiles of
BglII/XbaI, EcoRI/BglII, and EcoRI/XbaI, the genome size
was determined to be approximately at the range of 45.2
kb to 46.9 kb. The restriction analyses also indicated that
phage AB1 was a dsDNA virus. Determination of the
phage genome sequence is also underway.
Morphology study by transmission electron microscopy
Phage AB1 solution was filtrated with amicon-100 filter
to remove soluble macromolecules up to 100 KD in size.
After washing three times with 0.1 M ammonium acetate
solution, the retained phage solution was used directly
Figure 1 Restriction fragments analysis of phage genomic DNA. 
Phage genomic DNA was digested with EcoRI (lane1), XbaI (lane 2), BglII 
(lane 3), BglII/XbaI (lane 4), EcoRI/BglII (lane 5), and EcoRI/XbaI (lane 6), 
respectively. M1: molecular standard 1; M2: molecular standard 2.
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for negative staining. Images of phage AB1 were devel-
oped using transmission electron microscope (Fig. 2).
The results showed that phage AB1 had an icosahedral
head, about 50 nm in diameter, a 80 nm long non-con-
tractile tail, and collar or whisker structures, thus mor-
phologically similar to phages belonging to Siphoviridae
family.
Proteomic analysis of phage structural proteins
Purified phage particles were subjected to SDS-PAGE
and proteomic patterns were obtained after Coomassie
Blue G-250 staining and destaining (Fig. 3). Totally, five
major protein bands and six minor protein bands were
observed on the gel, with molecular weights ranging from
14 to 80 kilo-dalton.
Determination of the multiplicity of infection (MOI)
A. baumannii culture of exponential growth phase was
aliquot into vials with equal number of bacterial cells (108
cfu), which were infected with different amount of phage
AB1 as designed, then plated after 4 hours of incubation.
The group with a MOI of 10-4 gave the highest produc-
tion of phage progeny (4 × 1010 PFU/ml), and the MOI of
10-4 was chosen for the subsequent experiments in this
study.
Analysis of calcium effect on adsorption rate
Adsorption was the first step of phage infection of host
bacteria and is often affected by the presence of divalent
metal ions in the solution [20,21]. In the experiments, cal-
cium ions were added to test their effects on adsorption
efficacy. Phage AB1 and A. baumannii cells were mixed,
free phage numbers, left in the solution, were detected at
different time intervals. Statistical analysis showed signif-
icant differences existed between the two groups, and the
results indicated calcium ions might stabilize phage
adsorption process (Fig. 4).
Latent time and phage burst size
Single step growth experiment was performed to deter-
mine the latent time and phage burst size of phage AB1.
As shown in Fig. 5, a triphasic curve, including the latent
phase, rise phase, and plateau phase, was obtained. Using
these data, the latent time was determined to be about 18
minutes, and the burst size of phage AB1 was 409 PFU/
infected cell.
pH and thermal stability tests
Optimal pH was determined by testing the stability of
phage AB1 under different pHs. Almost no reduction of
infectious phage AB1 was observed after one hour incu-
bation at pH6.0, while different reduction percentages
Figure 2 Transmission electron micrograph of phage particles. Virions were negatively stained with potassium phosphotungstate. The bar rep-
resents a length of 100 nm or 50 nm. Blank arrows indicate collar or whisker structure of phage AB1.
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were obtained at other pHs, only 42.9% recovery of infec-
tious phage AB1 at pH5.0. These results suggested that
extreme pHs might affect phage AB1 stability (Fig. 6).
Thermal stability test was carried out to analyze heat
resistant capability of phage AB1 at pH6.0. The prelimi-
nary experiments showed that phage AB1 stock solution
retained almost 100% infection activity after incubation
at 37°C for one month (not shown), so higher tempera-
tures of 50°C, 60°C, 70°C, 80°C, and 90°C were chosen to
test thermal stability of phage AB1 (Fig. 7). The results
showed phage AB1 was extremely heat stable, 73.2% and
64.1% phages still remained alive after 60 minutes incuba-
tion at 50°C and 60°C, respectively; only 0.52% phages
were alive after 60 minutes incubation at 70°C; while
more than 99% phages lost their infection ability in 15
minutes at 80°C, or 5 minutes at 90°C.
Host range
The susceptibility to phage AB1 was also investigated
with four other clinical strains of A. baumannii, one clini-
cal strain of Stenotrophomonas maltophilia, and other lab
bacteria strains such as Pseudomonas aeruginosa PAK
and PAO1. No strain tested was found susceptible to
phage AB1. The results indicated phage AB1 had a nar-
row host range, consistent with the previous discoveries
[18]. Phages specifically targeting Acinetobacter spp. have
narrow host ranges, usually one host one phage, and it's
probably due to the existence of abundant surface bacte-
rial antigens on this bacterium. These antigens are suffi-
cient for different phage recognition [22].
The susceptibility test
Recently, most clinical isolates of A. baunannii were
found to be resistant to many antibiotics still in use, mak-
ing difficult the choice of an adequate antibiotic for the
treatment of A. baunannii infections [1-3]. In our study,
in vitro susceptibility tests of the 5 clinical strains were
carried out (table 1). Among the 15 antibiotics tested, all
strains were resistant to amoxicillin plus clavulanic acid,
ampicillin, cefoxitin, cephalothin, and nitrofurantoin.
Strain KD312 was only susceptible to 5 antibiotics, resis-
tant to 10 others including imipenem. Strain KD311, the
host of phage AB1, was susceptible to only 6 antibiotics
including imipenem but resistant to gentamicin, differing
from all other clinical isolates. All these data was coinci-
dent with the prevalence of multi-drug resistant A. baun-
annii infections throughout the world, indicating urgent
statue of new drugs discovery.
Figure 3 SDS-PAGE analysis of phage structural proteins. Phages 
particles from PEG precipitation was loaded directly. ?: solid arrows in-
dicate major proteins bands; Ќ: blank arrows show minor proteins 
bands.
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Figure 4 Adsorption rate test. At different time intervals, samples 
were taken from the supernatants to measure free phage particles. Di-
valent metal ions effect on adsorption rate was analyzed by adding 10 
mM CaCl2 to the mixture of phage AB1 and A. baumannii cells.
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Discussion
Most classified Acinetobacter  phages are tailed viruses
with double stranded DNA genomes. They are classified
into three families of the order of Caudovirales, including
Myoviridae, Podoviridae, and Siphoviridae [18,23]. One
exception is phage AP205 which is a ssRNA virus propa-
gating in Acinetobacter species [19]. It belongs to Leviviri-
dae family and tentatively classified into Levivius genus.
In this study, phage AB1 had an icosahedral head with a
non-contractile tail, and its genome was a molecule of
double stranded DNA, so it was tentatively classified as a
member of Siphoviridae family. Moreover, collar or whis-
ker structures were also observed in the phage AB1 (Fig.
2). Similar complexes have been found in Escherichia coli
phage T4 [24,25] and lactic acid bacteria phages [26].
These structures are involved in phage assembly, possible
regulation functions, sensing environmental conditions,
and holding long tail fibers in a retracted conformation
[25-30].
Thermal resistant phages were usually isolated from
extreme thermal habits [31,32], but they could also be
found in other environments. Recently, thermal resistant
phages have been isolated and characterized from various
dairy products [33,34]. Our experiment results showed
that phage AB1 was quite heat resistant, 0.03% phages
(1.23 × 107 PFU/ml) were still infectious even after 15 min
incubation at 90°C (Fig. 7). In the preliminary experi-
ments, phage amplification lysate (1010-1011 PFU/ml) was
heated directly at 100°C for stability test. After 5 minutes
boiling, the alive phage concentration was still about 105-
106 PFU/ml (data not shown). Previous studies showed
that media components of phage solution could affect the
thermal stability of phage [35]. For phage AB1, the lysate
supernatant of phage amplification was used directly in
thermal stability tests without any additional substance
added to LB medium. To demonstrate the mechanism of
its notable thermal resistance, more experiments need to
be done.
Nowadays, phage therapy has regained much attention
due to the emergence of drug resistant pathogens and the
dearth of new antibiotics in pipeline. In this study, phage
AB1 specific to A. baumannii was isolated and character-
Figure 5 One step growth experiment. Latent time and burst size of phage AB1 were inferred from the curve with a triphasic pattern. L: latent phase; 
R: rise phase; P: plateau phase.
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ized. The virus had some outstanding aspects including
rapid growth nature, high pH stability, and high thermal
resistance. All these characters made this phage very
promised for possible applications in eradication of A.
baumannii contaminations and or treatment of A. bau-
mannii infections. However, there was a great diversity of
surface antigens existed among the isolated clinical A.
baumannii  strains [22,36,37] and individual phage like
AB1 with narrow host range was not suitable to be used
directly [38]. In the future, more phages need to be iso-
lated for preparations of cocktails which might be the
best choice for phage applications.
Conclusions
Characterization of phage AB1 showed that it was very
efficient in lysing A. baunannii, combined with its out-
standing thermal stability, it may be a good candidate to
be used as an alternative nontoxic green sanitizer. How-
ever, host range tests showed phage AB1 did not infect
other A. baunannii clinical strains included in this study,
suggesting that more virulent bacteriophages specific to
different A. baunannii strains need to be screened and
collected in future. A pool of lytic phages might be more
useful against A. baunannii strains for possible phage
applications.
Materials and methods
Bacterial strains
This study included a clinical strain of Stenotrophomonas
maltophilia KD335 and 5 clinical strains of Acinetobacter
calcoaceticus-baumannii  complex, KD311, KD312,
KD331, KD332, and KD334. All of them were isolated
from hospitalized patients at Tianjin Children's Hospital,
Tianjin, P. R. China. Also, other bacteria strains were used
in phage host range test, including Pseudomonas aerugi-
nosa PAK and PAO1 lab strains.
Identification of bacterial strains by sequencing the 16s 
rRNA gene
Clinical strains were confirmed by sequencing the 16s
rRNA gene. Supernatant from boiled bacterial cells sus-
pended in distilled water was used directly as PCR tem-
plates. Universal primers, 27f (5' AGA GTT TGA TCC
TGG CTC AG 3') and 1492r (5' GGT TAC CTT GTT
ACG ACT T 3'), were adopted to amplify the 16s rRNA
genes [39]. Purified PCR products were sequenced
directly with primers. Sequences of 16s rRNA genes were
deposited in GenBank under accession numbers
FJ871007 (KD311), FJ871004 (KD312), FJ871006
(KD331), FJ871002 (KD332), FJ871003 (KD334), and
FJ871005 (KD335).
Figure 6 pH stability test of phage AB1. Phage was incubated under different pH values for one hour before determining the number of infectious 
phage particles.
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Phage enrichment and isolation
Luria-Bertani (LB) broth was used for liquid cultures, and
2% solid agar medium or 0.6% semi-solid agar medium
were used for bacteria plating and phage plaque-forming
assays, respectively. All incubations were carried out at
35°C. Briefly, identified A. baumannii clinical strains
were used as indicators for enriching and isolating viru-
l e n t  b a c t e r i o p h a g e s  f r o m  m a r i n e  s e d i m e n t  s a m p l e s.  I n
brief, marine sediment samples were taken from the
coastal seashore (38°59'N, 117°42'E) of China Bohai inner
sea. Weighed 5 grams of samples and resuspended in 30
ml LB, 300 μl overnight culture of A. baumannii was
added to the mixture, incubated at 35°C for 6 hours with
shaking to enrich A. baumannii-specific bacteriophages.
At the end of incubation, drops of chloroform were added
to the culture and the flask was left there for 15 minutes
without shaking. The culture was filtrated with Whatman
filter paper to remove soil particles, and the filtrate was
spun down at 11,000 g for 5 minutes to remove bacterial
cells and debris. Polyethylene glycol 6000 (PEG 6000) and
sodium chloride was added to the supernatant to the final
concentrations of 10% and 1 M, respectively. The solution
was incubated at 4°C overnight, spun at 11,000 g for 20
minutes. The pellet was dissolved in 1 ml phosphate-
buffered saline, the resulting solution was subjected to
0.45 μm filter to remove the residual bacterial cells. The
enriched phage solution was mixed with exponential
growth culture of A. baumannii and plated in semi-solid
agar medium after 15 minutes adsorption. Plaques
formed on the plates after 4 hours incubation at 35°C.
Single plaque was picked out for subsequent phage purifi-
cation and amplification [40,41].
Analysis of phage genomic DNA and total phage structural 
proteins
Molecular manipulations were carried out as previously
described [42]. Phage AB1 particles were amplified and
purified according to the phage isolation procedures and
bacteriophage DNA was isolated by the method
described previously [40,41,43]. Restriction endonu-
cleases were used to digest phage genomic DNA, and the
genome size was estimated by compilation of DNA frag-
ment sizes resulting from restriction enzymes digestion
profiles. DNA molecular standards were from Tiangen
Figure 7 Thermal stability tests of phage AB1. Samples were taken at different time intervals to titer the surviving particles and calculate the per-
centage of infectious phages.
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Biotech (Beijing) Co., Ltd. To prepare protein sample for
SDS-PAGE analysis, purified phage AB1 solution was
subjected to Amicon-100 filters, and the phage particles
were further washed three times with 0.1 M ammonium
acetate solution (pH7.0) to remove possibly existed resid-
ual bacterial proteins. Purified phage particles were sub-
jected to SDS-PAGE directly, and the gel stained with
Coomassie Blue G-250.
Morphology study by transmission electron microscope
Phage AB1 solution was filtrated with Amicon-100 filter
to remove soluble biological macromolecule fragments of
host bacteria. After washing three times with 0.1 M
ammonium acetate solution (pH7.0), the retained phage
solution was used directly for negative staining as
described previously [44]. Photographs were taken with a
JEOL1011 transmission electron microscope operating at
100 kV.
Determination of multiplicity of infection (MOI)
Serial dilutions of bacteriophage stock solution were
mixed with the same amount of A. baumannii cells. After
15 minutes adsorption, free bacteriophages were
removed by centrifugation at 5,000 g for 10 min, pellets
were resuspended with LB medium, and samples were
taken for bacteriophage titer analysis after 4 hours incu-
bation at 35°C.
Adsorption rate, latent period, and phage burst size
As described previously [20,21], 10 mM CaCl2 was added
to the infected culture to measure divalent metal ions
effects on adsorption rate of phage AB1, samples were
taken at different time intervals to analyze the free phage
particles in the solutions with and without addition of
calcium ions. One-step growth experiment was carried
out according to the previous descriptions [45,46] to
determine the latent period and phage burst size. In brief,
50 ml bacterial cells of A. baumannii KD311 were incu-
bated to mid-exponential-phase (OD600 = 0.4-0.6) and
harvested by centrifugation. The pellet was resuspended
in 0.5 ml fresh LB medium and mixed with 0.5 ml phage
AB1 solution (1 × 108 PFU/ml). Phage AB1 was allowed
to adsorb for 1 min and the mixture was subjected to cen-
trifugation immediately at 13,000 rpm for 30 seconds to
remove free phage particles. The pellet was resuspended
in 100 ml fresh LB medium and the culture was continu-
ously incubated at 35°C. Samples were taken at 3 min
intervals and phage titre was determined by the double-
layer-agar plate method. The results were analyzed and
the constant phage titer, which represented the number
of infective centres, along the latent stage was deduced.
The burst size of phage AB1 was calculated by dividing
the phage titers at plateau phase by the number of infec-
tive centres.
Table 1: In vitro susceptibility tests of 5 clinical A. baumannii strains
Antibiotics MIC (μg/ml)b
KD311 KD312 KD331 KD332 KD334
Amoxicillin/CAa •32 R ￿32 R ￿32 R ￿32 R ￿32 R
Ampicillin ￿32 R ￿32 R ￿32 R ￿32 R ￿32 R
Cefotaxime 16 I ￿64 R 16 I 16 I 16 I
Cefoxitin ￿32 R ￿32 R ￿32 R ￿32 R ￿32 R
Ceftazidime ￿8 S ￿32 R ￿8 S ￿32 R 16 I
Cephalothin ￿32 R ￿32 R ￿32 R ￿32 R ￿32 R
Gentamicin ￿16 R 1 S ￿0.5 S 2 S ￿0.5 S
Imipenem ￿4 S ￿6 R ￿4 S ￿4 S ￿4 S
Nalidixic Acid ￿16 S ￿16 S ￿16 S ￿16 S ￿16 S
Netilmicin ￿4 S 16 I ￿4 S ￿4 S ￿4 S
Nitrofurantoin ￿128 R ￿128 R ￿128 R ￿128 R ￿128 R
Pefloxacin ￿1 S ￿1 S ￿1 S ￿1 S ￿1 S
Ticarcillin 128 R 128 R ￿16 S ￿256 R ￿16 S
Tobramycin ￿0.5 S 1 S ￿0.5 S ￿0.5 S ￿0.5 S
Trimethoprim/Sulfa ￿320 R 40 S ￿10 S 80 R ￿10 S
a. clavulanic acid at a fixed concentration of 2 μg/ml.
b. R: resistant; S: susceptible; I: intermediate.Yang et al. BMC Microbiology 2010, 10:131
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pH stability and thermal stability test
pH stability and thermal stability tests were carried out as
previously described[47,48]. Briefly, certain amount of
phage particles were treated under specified conditions.
Samples were taken at different time intervals and super-
natants from centrifugation were used directly in the
assays. Initial phage concentration was about 3.5 × 1010
PFU/ml in LB medium.
Host range determination
108  bacterial cells were mixed with melted 0.6% agar
(50°C) and this mixture was poured on a 2% solid agar to
make double layer agar plates. After solidification, we
spotted the isolated bacteriophage stock solution on each
plate with different bacterium strain and observed
whether lysis plaques emerged.
The susceptibility test
BioMerieux Vitek 32 system (BioMerieux, Inc., USA) was
used in clinical samples diagnosis for bacterial identifica-
tions and antibiotics susceptibility tests.
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